Nectar Lifesciences Ltd. (NECLIFE) AI Stock Analysis

• Market Cap: ₹3.29B
• Dividend Yield: N/A
• Average Volume (3M): 74.28K
• Price to Earnings (P/E): 30.0
• Beta (1Y): 0.79
• Revenue Growth: -3.41%
• EPS Growth: -3028.44%
• Country: IN
• Employees: 1,686
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 224,260,970
• 10 Day Avg. Volume: 37,329
• 30 Day Avg. Volume: 74,278
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹14.50
• Price Target Upside: -1.09% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: ₹14.50 ▼(-1.09% Downside)

Nectar Lifesciences Ltd. faces significant challenges, primarily due to its negative earnings and bearish technical indicators. The financial performance shows volatility and inconsistency in profitability and cash flow, which are major concerns. The technical analysis indicates a strong downward trend, and the valuation metrics highlight the stock's unattractiveness due to negative earnings and lack of dividends. These factors collectively result in a low overall stock score.

Nectar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Nectar Lifesciences Ltd. (NECLIFE) is a leading player in the pharmaceutical and nutraceutical sectors, specializing in the production and export of high-quality honey, beekeeping products, and a range of herbal and natural health supplements. The company is committed to quality and sustainability, focusing on research and development to innovate its product offerings while adhering to international standards. NECLIFE caters to both domestic and international markets, leveraging its expertise in beekeeping and natural products to meet the growing demand for health-oriented solutions.

How the Company Makes Money

Nectar Lifesciences Ltd. generates revenue primarily through the manufacturing and sale of honey and other bee products, including propolis and royal jelly. Additionally, the company produces a variety of herbal and nutraceutical products, which contribute significantly to its revenue streams. NECLIFE's business model is bolstered by its export activities, as it ships products to various countries, tapping into the global demand for natural health products. The company also engages in strategic partnerships with international distributors and retailers, enhancing its market reach and driving sales. Moreover, the focus on quality assurance and certifications allows NECLIFE to command premium pricing, further contributing to its profitability.

Nectar Lifesciences Ltd. Financial Statement Overview

Summary

Nectar Lifesciences Ltd. faces challenges in maintaining consistent profitability and growth, as reflected in its income statement. The balance sheet indicates a stable capital structure but struggles with generating shareholder returns. Cash flow metrics show volatility, with some positive trends in recent periods. The company needs to address profitability and cash flow consistency to improve its financial health.

Income Statement

Nectar Lifesciences Ltd. has experienced significant volatility in its income statement metrics. The company reported a negative net profit margin and declining revenue growth rate in the latest period, indicating challenges in maintaining profitability and growth. The gross profit margin has also decreased over time, reflecting potential issues in cost management or pricing power. However, there were periods of positive EBIT and EBITDA margins, suggesting some operational efficiency during certain years.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the return on equity has been negative in recent periods, reflecting challenges in generating returns for shareholders. The equity ratio remains stable, suggesting a solid capital structure despite profitability issues.

Cash Flow

Cash flow analysis reveals fluctuating free cash flow growth, with a notable improvement in the latest period. The operating cash flow to net income ratio indicates some level of cash generation efficiency, although the free cash flow to net income ratio has been inconsistent. Overall, the cash flow position shows potential for improvement but remains volatile.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2020
Income Statement
Total Revenue	16.81B	16.70B	16.84B	16.69B	15.24B	23.66B
Gross Profit	4.29B	3.02B	4.82B	2.99B	579.91M	2.30B
EBITDA	1.80B	-245.66M	1.69B	1.61B	994.97M	2.20B
Net Income	170.01M	-1.14B	49.95M	250.47M	-241.83M	317.89M
Balance Sheet
Total Assets	0.00	20.47B	21.91B	23.91B	21.89B	26.33B
Cash, Cash Equivalents and Short-Term Investments	187.35M	272.63M	203.01M	182.35M	178.94M	214.22M
Total Debt	0.00	5.82B	6.36B	8.60B	7.54B	7.79B
Total Liabilities	-10.78B	10.91B	11.22B	13.03B	11.25B	14.97B
Stockholders Equity	10.78B	9.56B	10.69B	10.88B	10.65B	11.36B
Cash Flow
Free Cash Flow	0.00	1.26B	1.95B	700.35M	1.04B	2.30B
Operating Cash Flow	0.00	1.69B	2.25B	950.05M	1.34B	2.85B
Investing Cash Flow	0.00	-419.30M	-170.25M	166.44M	517.04M	-331.27M
Financing Cash Flow	0.00	-1.28B	-2.05B	-1.19B	-1.86B	-2.52B

Nectar Lifesciences Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Negative. The current price of 14.66 is below the 20-day moving average (MA) of 14.77, below the 50-day MA of 17.12, and below the 200-day MA of 26.55, indicating a bearish trend. The MACD of -0.65 indicates Negative momentum. The RSI at 41.25 is Neutral, neither overbought nor oversold. The STOCH value of 27.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NECLIFE.

Nectar Lifesciences Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	68 Neutral	₹6.17B	11.48		―	9.15%	88.32%
INDSWFTLAB	62 Neutral	₹6.18B	2.97		―	-68.96%	-30.30%
SAKAR	61 Neutral	₹7.30B	36.91		―	21.65%	73.84%
MEDICAMEQ	54 Neutral	₹4.71B	47.02		0.29%	-9.90%	33.18%
ZIMLAB	54 Neutral	₹3.62B	38.50		―	-3.36%	-47.58%
Sector *	51 Neutral	$7.95B	-0.40	-41.67%	2.21%	22.29%	-1.85%
NECLIFE	43 Neutral	₹3.29B	30.02		―	-3.41%	-3028.44%